Conmed Corp (CNMD)

$72.61

-0.03

(-0.04%)

Market is closed - opens 7 PM, 23 Apr 2024

Performance

  • $71.65
    $73.08
    $72.61
    downward going graph

    1.32%

    Downside

    Day's Volatility :1.96%

    Upside

    0.64%

    downward going graph
  • $70.57
    $137.65
    $72.61
    downward going graph

    2.81%

    Downside

    52 Weeks Volatility :48.73%

    Upside

    47.25%

    downward going graph

Returns

PeriodConmed Corp
3 Months
-26.1%
6 Months
-22.9%
1 Year
-38.09%
3 Years
-47.53%

Highlights

Market Capitalization
2.2B
Book Value
$27.12
Dividend Share
0.8
Dividend Yield
1.1%
Earnings Per Share (EPS)
2.04
PE Ratio
35.59
PEG Ratio
5.29
Wall Street Target Price
110.57
Profit Margin
5.18%
Operating Margin TTM
12.24%
Return On Assets TTM
3.47%
Return On Equity TTM
8.16%
Revenue TTM
1.2B
Revenue Per Share TTM
40.59
Quarterly Revenue Growth YOY
30.4%
Gross Profit TTM
575.7M
EBITDA
197.7M
Diluted Eps TTM
2.04
Quarterly Earnings Growth YOY
0.21
EPS Estimate Current Year
4.33
EPS Estimate Next Year
5.62
EPS Estimate Current Quarter
1.11
EPS Estimate Next Quarter
0.9

Analyst Recommendation

Buy
    71%Buy
    28%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Conmed Corp(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
11
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 52.28%

Current $72.61
Target $110.57

Company Financials

FY18Y/Y Change
Revenue
859.6M
↑ 7.94%
Net Income
40.9M
↓ 26.37%
Net Profit Margin
4.75%
↓ 2.22%
FY19Y/Y Change
Revenue
955.1M
↑ 11.11%
Net Income
28.6M
↓ 29.95%
Net Profit Margin
3.0%
↓ 1.75%
FY20Y/Y Change
Revenue
862.5M
↓ 9.7%
Net Income
9.5M
↓ 66.75%
Net Profit Margin
1.1%
↓ 1.9%
FY21Y/Y Change
Revenue
1.0B
↑ 17.18%
Net Income
62.5M
↑ 557.16%
Net Profit Margin
6.19%
↑ 5.09%
FY22Y/Y Change
Revenue
1.0B
↑ 3.45%
Net Income
-80.6M
↓ 228.84%
Net Profit Margin
-7.71%
↓ 13.9%
FY23Y/Y Change
Revenue
1.2B
↑ 18.7%
Net Income
64.5M
↓ 179.99%
Net Profit Margin
5.19%
↑ 12.9%
Q3 FY22Q/Q Change
Revenue
275.1M
↓ 0.76%
Net Income
46.2M
↓ 127.42%
Net Profit Margin
16.78%
↑ 77.49%
Q4 FY22Q/Q Change
Revenue
250.9M
↓ 8.8%
Net Income
26.6M
↓ 42.4%
Net Profit Margin
10.6%
↓ 6.18%
Q1 FY23Q/Q Change
Revenue
295.5M
↑ 17.78%
Net Income
1.8M
↓ 93.16%
Net Profit Margin
0.62%
↓ 9.98%
Q2 FY23Q/Q Change
Revenue
317.7M
↑ 7.51%
Net Income
13.7M
↑ 654.92%
Net Profit Margin
4.32%
↑ 3.7%
Q3 FY23Q/Q Change
Revenue
304.6M
↓ 4.12%
Net Income
15.8M
↑ 15.33%
Net Profit Margin
5.2%
↑ 0.88%
Q4 FY23Q/Q Change
Revenue
327.0M
↑ 7.38%
Net Income
33.1M
↑ 108.82%
Net Profit Margin
10.11%
↑ 4.91%
FY18Y/Y Change
Total Assets
1.4B
↑ 0.82%
Total Liabilities
706.9M
↓ 2.71%
FY19Y/Y Change
Total Assets
1.8B
↑ 29.65%
Total Liabilities
1.1B
↑ 50.61%
FY20Y/Y Change
Total Assets
1.8B
↓ 1.32%
Total Liabilities
1.0B
↓ 2.07%
FY21Y/Y Change
Total Assets
1.8B
↑ 0.82%
Total Liabilities
980.6M
↓ 5.95%
FY22Y/Y Change
Total Assets
2.3B
↑ 30.1%
Total Liabilities
1.6B
↑ 58.28%
FY23Y/Y Change
Total Assets
2.3B
↑ 0.11%
Total Liabilities
1.5B
↓ 5.56%
Q3 FY22Q/Q Change
Total Assets
2.3B
↑ 10.61%
Total Liabilities
1.6B
↑ 12.61%
Q4 FY22Q/Q Change
Total Assets
2.3B
↑ 0.24%
Total Liabilities
1.6B
↓ 1.5%
Q1 FY23Q/Q Change
Total Assets
2.3B
↑ 0.98%
Total Liabilities
1.6B
↑ 1.01%
Q2 FY23Q/Q Change
Total Assets
2.3B
↑ 0.11%
Total Liabilities
1.5B
↓ 1.6%
Q3 FY23Q/Q Change
Total Assets
2.3B
↑ 0.13%
Total Liabilities
1.5B
↓ 0.85%
Q4 FY23Q/Q Change
Total Assets
2.3B
↓ 1.1%
Total Liabilities
1.5B
↓ 4.16%
FY18Y/Y Change
Operating Cash Flow
74.7M
↑ 13.93%
Investing Cash Flow
-16.5M
↓ 43.19%
Financing Cash Flow
-72.3M
↑ 107.18%
FY19Y/Y Change
Operating Cash Flow
95.1M
↑ 27.35%
Investing Cash Flow
-387.7M
↑ 2248.47%
Financing Cash Flow
300.9M
↓ 516.36%
FY20Y/Y Change
Operating Cash Flow
64.5M
↓ 32.17%
Investing Cash Flow
-13.6M
↓ 96.48%
Financing Cash Flow
-52.1M
↓ 117.3%
FY21Y/Y Change
Operating Cash Flow
111.8M
↑ 73.2%
Investing Cash Flow
-14.9M
↑ 9.0%
Financing Cash Flow
-101.5M
↑ 95.06%
FY22Y/Y Change
Operating Cash Flow
33.4M
↓ 70.15%
Investing Cash Flow
-249.5M
↑ 1578.52%
Financing Cash Flow
225.0M
↓ 321.57%
Q3 FY22Q/Q Change
Operating Cash Flow
25.9M
↑ 38.15%
Investing Cash Flow
-91.3M
↓ 38.45%
Financing Cash Flow
46.9M
↓ 70.54%
Q4 FY22Q/Q Change
Operating Cash Flow
-11.6M
↓ 144.79%
Investing Cash Flow
-6.3M
↓ 93.08%
Financing Cash Flow
11.5M
↓ 75.43%
Q1 FY23Q/Q Change
Operating Cash Flow
-3.8M
↓ 66.83%
Investing Cash Flow
-4.3M
↓ 32.67%
Financing Cash Flow
5.4M
↓ 53.54%
Q2 FY23Q/Q Change
Operating Cash Flow
26.7M
↓ 793.35%
Investing Cash Flow
-5.5M
↑ 29.97%
Financing Cash Flow
-19.8M
↓ 469.85%
Q3 FY23Q/Q Change
Operating Cash Flow
46.1M
↑ 72.94%
Investing Cash Flow
-5.4M
↓ 2.44%
Financing Cash Flow
-37.2M
↑ 88.15%

Technicals Summary

Sell

Neutral

Buy

Conmed Corp is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Conmed Corp
Conmed Corp
-5.24%
-22.9%
-38.09%
-47.53%
-47.53%
Stryker Corporation
Stryker Corporation
-7.29%
23.47%
7.74%
21.88%
74.06%
Boston Scientific Corp.
Boston Scientific Corp.
0.06%
34.31%
31.15%
57.57%
87.6%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-7.75%
24.46%
-3.21%
-10.62%
42.46%
Abbott Laboratories
Abbott Laboratories
-2.98%
12.01%
-2.83%
-13.13%
43.98%
Medtronic Plc
Medtronic Plc
-3.21%
9.79%
-10.17%
-39.42%
-5.32%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Conmed Corp
Conmed Corp
35.59
35.59
5.29
4.33
0.08
0.03
0.01
27.12
Stryker Corporation
Stryker Corporation
39.69
39.69
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
63.01
63.01
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.37
37.37
5.19
2.75
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
32.79
32.79
5.99
4.33
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.14
25.14
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Conmed Corp
Conmed Corp
Buy
$2.2B
-47.53%
35.59
5.18%
Stryker Corporation
Stryker Corporation
Buy
$124.6B
74.06%
39.69
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$99.1B
87.6%
63.01
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$51.7B
42.46%
37.37
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$182.7B
43.98%
32.79
13.96%
Medtronic Plc
Medtronic Plc
Buy
$105.2B
-5.32%
25.14
13.0%

Institutional Holdings

  • BlackRock Inc

    16.34%
  • Vanguard Group Inc

    11.11%
  • Capital Research Global Investors

    8.96%
  • Earnest Partners LLC

    7.62%
  • State Street Corporation

    3.86%
  • Bank of America Corp

    3.22%

Corporate Announcements

  • Conmed Corp Dividends March,2024

    In the quarter ending March,2024. Conmed Corp has declared dividend of $0.2

    Read More

Company Information

conmed corporation is a global medical technology company that specializes in the development and sale of surgical and patient monitoring products and services that allow our physician customers to deliver high quality care and as a result, enhanced clinical outcomes for their patients. our products are technological leaders in the specialties that we serve: orthopaedics, general surgery, gynecology, gastroenterology, pulmonology, and anesthesiology. conmed's mission, and the focus of every employee around the world, is to improve the quality of health care by designing, producing and marketing innovative, high-quality products. our emphasis is on our customer’s satisfaction and on our enhanced patient outcomes. we strive to demonstrate thoughtful leadership, provide meaningful opportunities for employees, and be a responsible member of the local communities in which we conduct business. conmed is headquartered in beautiful, upstate new york (utica), and employs approximately 3500

Organization
Conmed Corp
Employees
4000
CEO
Mr. Curt R. Hartman
Industry
Health Technology

FAQs